Compare Stocks

→ Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NVH Novoheart	C$0.53 +1.9%	C$0.53	C$0.26 ▼ C$0.72	C$99.98M	N/A	33,593 shs	23,066 shs
OKYO OKYO Pharma	$1.47 +1.4%	$1.45	$0.92 ▼ $3.25	$42.38M	0.04	151,948 shs	11,767 shs
ORPH Orphazyme A/S		$1.43	$0.51 ▼ $77.77	$30.72M	1.68	1.37 million shs	941,400 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NVH Novoheart	0.00%	0.00%	0.00%	0.00%	0.00%
OKYO OKYO Pharma	+2.84%	-1.36%	+0.69%	-8.81%	+14.17%
ORPH Orphazyme A/S	0.00%	0.00%	0.00%	0.00%	0.00%

Move Your Money Before May 22 (Ad)

The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals.

Here's where Dr. David Eifrig says to move your money immediately.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NVH Novoheart	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	3.1431 of 5 stars	3.5	5.0	0.0	0.0	2.8	1.7	0.6
ORPH Orphazyme A/S	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NVH Novoheart	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	3.00	Buy	$7.00	376.16% Upside
ORPH Orphazyme A/S	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest NVH, OKYO, and ORPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/22/2024	OKYO OKYO Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$6.00 ➝ $7.00

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NVH Novoheart	C$423.50K	236.08	C$0.07 per share	7.46	C$0.12 per share	4.34
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.08) per share	N/A
ORPH Orphazyme A/S	N/A	N/A	N/A	N/A	$2.74 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NVH Novoheart	N/A	-C$0.04	N/A	∞	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	-$13.27M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/20/2024 (Estimated)
ORPH Orphazyme A/S	-$97.01M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NVH Novoheart	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A
ORPH Orphazyme A/S	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NVH Novoheart	27.62	6.13	6.05
OKYO OKYO Pharma	N/A	N/A	N/A
ORPH Orphazyme A/S	0.14	1.80	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
NVH Novoheart	N/A
OKYO OKYO Pharma	2.97%
ORPH Orphazyme A/S	10.74%

Insider Ownership

Company	Insider Ownership
NVH Novoheart	N/A
OKYO OKYO Pharma	40.46%
ORPH Orphazyme A/S	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
NVH Novoheart	N/A	188.64 million	N/A	Not Optionable
OKYO OKYO Pharma	8	28.83 million	17.17 million	Not Optionable
ORPH Orphazyme A/S	141	35.31 million	N/A	Not Optionable

NVH, OKYO, and ORPH Headlines

Source	Headline
	Anopheles stephensi Mosquitoes: An Old Problem, A New Threat to Malaria Mitigation wilsoncenter.org - April 26 at 2:41 AM
	Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients msn.com - April 20 at 10:46 AM
	Olympic torch makes Acropolis overnight stop a week before handover to Paris organizers msn.com - April 19 at 6:28 PM
	Syphilis cases in Colorado are exploding. The state just issued a public health order to try to stop that. coloradosun.com - April 19 at 6:28 PM
	Inside Gen Alpha’s controversial obsession with skincare nbcnews.com - April 18 at 3:22 PM
	It’s the first drug shown to slow Alzheimer’s. Why is is it off to a slow start? msn.com - April 13 at 11:29 AM
	Lysine Is Important for the Body, and Is Generally a Safe Supplement msn.com - April 12 at 12:36 PM
	STALICLA Appoints Dr. Thomas Blaettler, MD albawaba.com - April 12 at 2:08 AM
	Zevra Therapeutics: Strong Buy on Strategic Financing and Promising Drug Portfolio markets.businessinsider.com - April 11 at 9:07 PM
	From fungi to feast: The rise of Mycoprotein as a sustainable protein solution msn.com - April 8 at 4:17 PM
	AliExpress Under Fire: Unsafe Phthalate Levels Found in Children's Items econotimes.com - April 8 at 4:17 PM
	Ask A Doctor: What Diseases Cause Encephalopathy? msn.com - April 3 at 10:33 PM
	Chemists discover a key protein in how lysosomes work msn.com - April 1 at 2:52 PM
	BMS’ Zeposia Fails to Meet Primary Endpoint in Phase III Crohn’s Trial biospace.com - March 30 at 5:48 PM
	University of Chicago chemists discover a key protein in how lysosomes work news.uchicago.edu - March 29 at 9:45 PM
	Orry refuses to shake woman’s hand citing ‘germs,’ threatens legal action after her video msn.com - March 28 at 8:40 PM
	A Guide To Pokémon's Poison Type msn.com - March 28 at 8:40 PM
	Understanding what causes trastuzumab's cardiotoxicity msn.com - March 18 at 10:53 PM
	How a brash, red-haired orphan from P.E.I. continues to be a worldwide sensation msn.com - March 16 at 5:47 PM
	Sindica - A Novel, Patented Post-emergence Herbicide for Sugarcane from Atul msn.com - March 14 at 3:51 PM
	AlphaTheta dives into rotary world with launch of the euphonia: a 4-channel rotary mixer djtechtools.com - March 14 at 3:51 PM
	Here are the concerns with artificial food dyes, as California weighs a ban in schools kvpr.org - March 14 at 3:51 PM
	Sharing a Drink With Orphaned Opossum Babies msn.com - March 12 at 8:25 PM
	Zevra adds bull at William Blair despite delay in arimoclomol decision msn.com - March 12 at 3:14 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Novoheart

CVE:NVH

Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.

OKYO Pharma

NASDAQ:OKYO

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Orphazyme A/S

NASDAQ:ORPH

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial